Reactions 1871, p133 - 4 Sep 2021
Covid-19-vaccine-pfizer-biontech
SErythematous and purpuric rash: 2 case report
A case series described two women aged 60 years and 75 years, who developed erythematous and purpuric rash following an administration of Covid-19-vaccine-pfizer-biontech [dose and route not stated].
Patient 1: The 60-year-old woman, who had a history of hypothyroidism developed a rash 2 weeks after the administration of Covid-19-vaccine-pfizer-biontech [Pfizer-BioNTech COVID-19 vaccine]. Two days later, she presented to a dermatology with a widespread symmetrical erythematous and purpuric eruption mostly affecting legs. Skin biopsies revealed eosinophils and the direct immunofluorescence microscopy result was negative. She received prednisolone and unspecified topical treatments. Seven days later, the rash was gradually improved.
Patient 2: The 75-year-old woman, who had a history of hypertension received first dose of Covid-19-vaccine-pfizer-biontech.
Two days following vaccination, she developed a confluent erythematous rash on her torso and a symmetrical purpuric rash over the gaiter areas of legs. She received prednisolone for 5 days. The rash was fully resolved by day 10. She did not experience any reaction following the second dose of the Pfizer-BioNTech COVID-19 vaccine.
Lam M, et al. Ribonucleic acid COVID-19 vaccine-associated cutaneous adverse drug events: a case series of two patients. Clinical and Experimental Dermatology 46:
1131-1134, No. 6, Aug 2021. Available from: URL: http://doi.org/10.1111/ced.14673 803592200
1
Reactions 4 Sep 2021 No. 1871 0114-9954/21/1871-0001/$14.95 Adis © 2021 Springer Nature Switzerland AG. All rights reserved
